This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Understanding a Coin-Flip Game Can Make You a Smarter Biotech Investor

Is this biotech company a good investment? Like with the coin flip game, the answer depends on the cost -- in this case the price of the biotech company's stock. A share price below $50 would mean the company is undervalued and therefore a good investment. If the current stock price exceeds $50, the company is overvalued.

Of course, biotech investment decisions are not nearly as simplistic as my example, mainly because the nailing down the correct probability of a drug approval and the value of that drug approval (the discounted cash flow) is a significant challenge. In reality, these numbers have to be estimated with the associated errors.

Even setting that aside, this sort of analysis highlights two critical points that biotech investors should always keep in mind. First, a company could have a very low probability of success and be undervalued. For instance, one could assume a 2 percent chance of success with a $100 DCF, which creates an expected return of $2. If the share price is under $2, then an investment has a positive expected utility (profit) even though you expect the drug to ultimately fail. In many ways, I think this is what many Biodel (BIOD) bulls argue: The odds of success for its rapid-acting, mealtime insulin are low but the stock is cheap enough to make it a good investment.

Second, a company with a high probability of success can be overvalued. For instance, one could assume a 98% chance of success with a $100 DCF, which generates a $98 expected benefit. If the price is over $98 then the company is overvalued. A good real-life example is the bear thesis on Seattle Genetics (SGEN): The Adcetris label will be expanded but the company's current valuation more than takes that into account.

I've simplified discussion of how expected utility theory plays a role in biotech investing. Clearly, the method can be made much more complicated with the introduction of more variables. The key take-home point is that not all biotech companies with a high probability of success are good investments, nor are all biotech companies with a low probability of success bad investments.

Perhaps the only truism is that holding all else constant, as the share price decreases the more undervalued a company becomes. The key there is "hold all else constant" because you need to be sure that the falling share price is not caused by changing probability of success or lower commercial opportunity.

Sobek is long Seattle Genetics.

David Sobek has been writing on biotech for a number of years through various outlets with a general focus on small cap oncology and antibiotics companies. He received his PhD in political science from Pennsylvnia State Univeristy in 2003 and a BA in international relations from The College of William and Mary in 1997.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs